PCCP

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about *Accepted Manuscripts* in the **Information for Authors**.

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard <u>Terms & Conditions</u> and the <u>Ethical guidelines</u> still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.



www.rsc.org/pccp

ARTICLE



Crystallization of Undercooled Liquid Fenofibrate

Esther Amstad^{a,b}, Frans Spaepen^a, David A. Weitz^{a,c*}

Received 00th January 20xx, Accepted 00th January 20xx

DOI: 10.1039/x0xx00000x

www.rsc.org/

Formulation of hydrophobic drugs as amorphous materials is highly advantageous as this increases their solubility in water and therefore their bioavailability. However, many drugs have a high propensity to crystallize during production and storage, limiting the usefulness of amorphous drugs. We study the crystallization of undercooled liquid fenofibrate, a model hydrophobic drug. Nucleation is the rate-limiting step; once seeded with a fenofibrate crystal, the crystal rapidly grows by consuming the undercooled liquid fenofibrate. Crystal growth is limited by the incorporation of molecules into its surface. As nucleation and growth both entail incorporation of molecules into the surface, this process likely also limits the formation of nuclei and thus the crystallization of undercooled liquid fenofibrate, contributing to the good stability of undercooled liquid fenofibrate against crystallization.

Introduction

The bioavailability of hydrophobic drugs is often limited by their poor water solubility; this can severely reduce their effectiveness as medication.¹ The effectiveness of such drugs strongly increases if they are formulated as amorphous materials, as the amorphous phase has a higher free energy and thus a higher solubility; hence, it dissolves faster and in larger quantities than the crystal.^{2,3} However, it is difficult to make drugs amorphous as many of them have a high propensity to crystallize.⁴ To overcome this difficulty, large quantities of crystallization-inhibiting polymers can be added.⁵ Although drugs can be made amorphous, their use is still very limited as it is even more difficult to prevent crystallization during storage; this is especially the case if drugs are kept at temperatures close to their glass transition temperature, T_g , as many drugs are.^b This spontaneous phase transformation occurs even if they are stabilized with crystallization-inhibiting polymers;⁷ it uncontrollably changes the bioavailability and limits the utility of amorphous drugs. A qualitative improvement of the stability of amorphous drugs requires a better understanding of the most important parameters that drive crystallization. This understanding is difficult to obtain, as the crystallization of amorphous drugs, formulated in the presence of polymeric additives, strongly depends on the

additive itself.⁵ It is much easier to gain this understanding from additive-free amorphous drugs; such drugs can be conveniently produced using a microfluidic nebulator.⁸ However, studies on the crystallization of pure amorphous drugs remain rare.

In this paper, we study the crystallization of undercooled liquid fenofibrate, a hydrophobic model drug. Even though its crystallization is limited by nucleation, both the nucleation and growth processes entail the incorporation of solute molecules into crystalline surfaces; hence, their rates are influenced by similar kinetic parameters. We study crystal growth since this process is easier to visualize; it is diffusion-limited and thus strongly temperature-dependent. However, diffusion only accounts for the frequency with which molecules impinge on a surface; it does not account for the probability of impinging molecules to insert themselves into the crystal. This probability is very low for fenofibrate, an anisotropic molecule, and slows down the crystal growth by more than two orders of magnitude under the conditions of these experiments.

Results and discussion

We fabricate the nebulator from poly(dimethyl siloxane) (PDMS) using soft lithography.⁹ It contains two inlets for liquids and six inlets for air. Liquid is injected into the main channel before the first pair of air inlets intersects the main channel at an angle of 135°. The air pushes ethanol towards the four channel walls, forming thin ethanol films that flow along these walls while the air flows through the center of the channel. The subsequent air inlets intersect the main channel at an angle of 45°, as shown in Figure S1; the air inserted through these inlets accelerates the air in the main channel, thereby thinning the ethanol films. The last junction is three-dimensional (3D)¹⁰ to push the ethanol films away from all

^a School of Engineering and Applied Sciences, Harvard University, 02138 Cambridge, Massachusetts, USA.

^{b.} Institute of Materials, Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland.

^{c.} Department of Physics, Harvard University, 02138 Cambridge, Massachusetts, USA.

^{*}Electronic Supplementary Information (ESI) available: [details of any supplementary information available should be included here]. See DOI: 10.1039/x0xx00000x

ARTICLE

four walls of the last part of the main channel, thereby breaking the ethanol films into very small drops that rapidly dry. $^{\rm 8}$

We use fenofibrate as a hydrophobic model drug; amorphous fenofibrate is an undercooled liquid at room temperature since it has a glass transition temperature, T_g , of -20°C^{7} and a melting temperature, T_m , of 80°C .¹¹ We dissolve fenofibrate in ethanol at 5 mg/ml, and inject the solution through one liquid inlet at 1 ml/h using syringe pumps; we block the second liquid inlet to avoid leakage of the liquid and the air. We introduce air by applying 0.28 MPa to all the air inlets and collect the spray dried undercooled liquid drops 15 cm apart from the nozzle on a flat substrate.⁸

The nebulator produces amorphous undercooled liquid fenofibrate drops with diameters as small as 14 nm;¹² the volume of a single drop is as low as 10⁻²¹ l. However, as amorphous fenofibrate is an undercooled liquid at room temperature, drops coalesce as soon as they come in contact with each other. The larger volume of the resulting coalesced drops increases the probability for a crystal nucleus to form in each drop.¹³ Remarkably, even if we coalesce sufficient drops to form a drop as large as 600 pl, fenofibrate remains amorphous for at least 5 days if stored at room temperature under ambient conditions. However, once seeded with a crystal nucleus of a diameter between 35 μ m and 70 μ m, three dimensional crystals grow very rapidly by consuming some of the amorphous phase; it takes less than a minute to grow dendritic crystals several 100 µm in size, as shown in time-lapse optical micrographs in Figures 1a-d, indicating that nucleation is the ratelimiting step in the crystallization process.





The formation of crystal nuclei is difficult to study quantitatively. However, nucleation involves the incorporation of solute molecules into a crystal surface; the same process also occurs during crystal growth, which is much easier to access experimentally. Thus, we estimate the temperature-dependent rate at which molecules are incorporated into the crystal surface by quantifying the growth kinetics of the dendrite tips. We measure the distance dendrite tips grow per unit as a function of the temperature, T, using time-lapse optical micrographs and calculate the dendrite growth velocity. During the early and intermediate stages of the crystal growth the growth rate is, within experimental error, constant. By contrast, the growth rate continuously decreases during the final stages of crystal growth. Hence, we only quantify the growth rate during the early and intermediate stages. As we increase the temperature, the undercooling $\Delta T = T_m - T$ decreases; here T_m is the melting temperature of fenofibrate; this reduces the driving force for crystal growth.¹³ Despite the reduced driving force, crystals grow faster with increasing temperature, as shown in Figure 1e.

The increasing growth rate of crystals with increasing temperature indicates that crystal growth is diffusion-limited. Factors limiting the growth rate of fenofibrate crystals must thus include the jump frequency of the molecule from the liquid to the crystal, k, and the probability that impacting molecules are incorporated into the surface, which is described by the site factor, f. The diffusional jump frequency $k = \frac{6D}{\lambda^2}$ depends on the diffusion coefficient, D, as well as the jump distance, λ , which we take as the longest dimension of a fenofibrate molecule, 1.5 nm;¹⁴ it is independent of the mechanism by which crystals grow.

To investigate the growth mechanism, we determine the temperature-dependence of f. We describe the growth velocity as $v=kf\lambda(1-\exp\left(-rac{\Delta\mu}{k_BT}
ight));$ here, $\Delta\mu$ is the difference in the chemical potential of a molecule in the crystal and in the undercooled liquid, k_B the Boltzmann constant, and T the absolute temperature. We calculate $\Delta \mu = \frac{\Delta H_m \Delta T}{T_m N_{Av}}$ as a function of the undercooling using the latent heat of fenofibrate, $\Delta H_m =$ 28.8 kJ/mol, and its melting temperature, $T_m = 80^{\circ}$ C, which we determine with differential scanning calorimetry (DSC) (Figure 2); here N_{Av} is Avogadro's number. In addition, we quantify the diffusional jump frequency $k = \frac{6D}{\lambda^2} = \frac{2k_BT}{\pi\eta\lambda^3}$ using the Stokes-Einstein relation for the last equality and the temperature-dependent values for the viscosity of fenofibrate, η .⁴ We subsequently calculate f as a function of temperature. At room temperature, the site factor is as low as 0.01 and further decreases with increasing temperature, as shown in Figure 1f. These small values slow down crystal growth. Moreover, the increase in f with increasing undercooling, ΔT , suggests that the crystal growth is limited by the layer nucleation on the crystal face, as detailed in the supporting information.

The key parameter in the nucleation of a crystal is the ledge energy, γ_{le} , associated with the side surface of the layer nucleus.¹³ To compute γ_{le} , we express the site factor as $f = (\lambda^2 n_s^*)^{\frac{1}{3}} f_l^{\frac{2}{3}} i_s^{\frac{1}{3}}$; here n_s^* is the surface concentration of critical layer nuclei, f_l is the site factor for the ledge of a layer, and i_s^* the number of molecules along the edge of a critical layer nucleus. The site factor for a ledge is typically much larger than that for a surface since ledges are usually rough;¹⁵ we thus take $f_l \approx 1$. The number of molecules in a critical layer nucleus is small and we approximate $i_s^* \approx 1$. We confirm the accuracy of this assumption by determining the size of

the critical nucleus after we have calculated the ledge energy. The surface concentration of critical nuclei, $n_s^* = \frac{1}{\lambda^2} \exp\left(-\frac{w_s^*}{k_DT}\right)$,



Figure 2: Differential scanning calorimetry (DSC) traces of spray dried undercooled liquid fenofibrate drops with a diameter of 14 nm. Traces were acquired (1) 0 d, (2) 4 d, and (3) 8 d after preparation. Samples are stored in an aluminum DSC pan under ambient conditions. (4) Reference spectrum of bulk fenofibrate.

depends on the work for these critical nuclei to form, $w_s^* = \pi \frac{\gamma_e^2 \lambda}{\Delta \mu_v}$. This work is a balance between the energy per unit length required to form a ledge, γ_{le} , and the energy gained by forming a crystal. The gained energy is equal to the difference in the chemical potential per unit volume, $\Delta \mu_v = \frac{\Delta \mu}{\overline{v}}$; here \overline{V} is the molecular volume of fenofibrate. Thus, we approximate the interfacial site factor as $f = \exp\left(-\frac{w_s^*}{3k_BT}\right)$. Using the values of f, shown in Figure 1f, we calculate the ledge energy to be $\gamma_{le} = 14 \ mJ/m^2$. Indeed, this value is nearly independent of the temperature, despite the temperature-dependence of f and $\Delta \mu_v$, as shown in the supporting information, supporting the validity of the layer nucleation mechanism.

As crystallization of fenofibrate is limited by the nucleation of a crystal, the stability of amorphous fenofibrate strongly depends on the rate at which stable crystal nuclei form. We experimentally

determine an upper limit of the crystal nucleation rate, $I < \frac{1}{V_d \Delta t'}$ here V_d is the volume of a drop and Δt the time it takes for a drop to crystallize. We spray dry undercooled liquid fenofibrate drops with different volumes and measure the time it takes them to crystallize. Well-separated drops as small as 10⁻²¹ l remain liquid for more than 7 months if stored at room temperature.⁸ If we increase the volume of the drops to 0.1 - 1 pl, they show no sign of crystallinity after 1 day storage in an aluminum DSC pan, as indicated by the absence of any melting peaks in DSC trace 1 of Figure 2. However, they do start to crystallize within 4 days, as indicated by the melting peak in trace 2 of Figure 2. Even more of these drops spontaneously crystallize after having been stored for 8 days, as indicated by the larger melting peak in trace 3 in Figure 2. If we increase the volume of drops by 11 orders of magnitude to $V_d \approx$ 600 pl, they only remain liquid for approximately $\Delta t = 5$ days. Thus, we obtain $I < rac{1}{V_d \Delta t} pprox 3.8 imes 10^6 m^{-3} s^{-1}$ at room temperature.

A crystal nucleus becomes supercritical and thus stable when the energy gained from adding an additional molecule $\Delta\mu$, is higher than the energy needed to create additional crystal-melt interface; the energy of this additional crystal-melt interface per unit area is γ . For a spherical nucleus, the critical radius is $r^* = \frac{2\gamma}{\Delta\mu_v}$. To determine r^* , we use the classical nucleation theory to describe the

nucleation rate $I = fknZexp(-\frac{w^*}{k_B T})$; here, n is the number of molecules per unit volume, Z the Zeldovich factor, and $w^* = \frac{16\pi}{3} \frac{\gamma^3}{(\Delta \mu_v)^2}$ the work to form a spherical nucleus.¹³ From the density of fenofibrate, we get $n = 2 \times 10^{27} m^3 s^{-1}$. Taking the lower limit of $Z \ge 0.01$,¹³ the measured values for f and $\Delta \mu_v$, and the calculated values for k, we estimate a lower limit for $\gamma \ge 15 mJ/m^2$; this value is close to that of the ledge energy γ_{le} . At room temperature, this surface energy results in a radius of a critical nucleus of approximately 1.8 nm; such a nucleus contains approximately 26 fenofibrate molecules.¹⁴ Despite of the small size of the critical crystal nucleus, it takes time for them for such nuclei to form, as the probability for fenofibrate molecules to incorporate in a crystal, f, is very low.

Once the crystal growth is complete, a particle of radius r_p is formed whose chemical potential differs from that of the bulk by $\Delta \mu = \frac{2\gamma_c \overline{\nu}}{r}$; here γ_c is the crystal free energy. Since the surface energy of the liquid, γ_l , is usually lower than that of the crystal, γ_c ,



Figure 3: (a-d) Scanning electron micrographs of undercooled liquid fenofibrate drops spray dried by applying (a) 0.28 MPa, (b) 0.24 MPa, (c) 0.21 MPa, and (d) 0.17 MPa to the inlets of the microfluidic nebulator. (e) Size-dependent melting point of fenofibrate. The slope of the linear fit through the origin allows calculation of $\Delta \gamma$, the difference of the surface energies between the free surfaces at the liquid and crystalline phase.

ARTICLE

sics Accepted Manusc

chemical

Journal Name

ARTICLE

the melting temperature is shifted, according to the Gibbs-Thompson relation $\Delta T = T_{m,b} - T_{m,p} = \frac{2\Delta \gamma \nabla T_m}{r\Delta H_m}$; here $T_{m,b}$ is the melting point of the bulk, $T_{m,p}$ that of the particle, and $\Delta \gamma = \gamma_c - \gamma_l$. We spray dry particles with a narrow size distribution, having diameters between 20 nm and 25 nm by controlling the pressure applied to the air inlets of the nebulator.⁸ We measure their sizes from scanning electron microscopy (SEM) images, as shown in Figures 3a-d, quantify ΔT using differential scanning calorimetry (DSC),⁸ and plot ΔT as a function of the inverse particle diameter. Indeed, the melting point depression increases with decreasing particle size, as shown in Figure 3e. We perform a linear fit of the data through the origin to obtain the difference between the surface energy of the crystal and the liquid $\Delta \gamma = 4.5 mJ/m^2$, a plausible value.

Conclusions

The crystallization of undercooled liquid fenofibrate is limited by nucleation. Even though we only show that the incorporation probability of molecules arriving at the surface is the rate-limiting step of the crystal growth, we expect the same parameter also to limit the nucleation as both processes, nucleation and growth, entail the incorporation of molecules into a crystal surface. Thus, the low insertion probability of fenofibrate molecules into the crystal slows down the nucleation of crystals, thereby enhancing the stability of the undercooled liquid. This is a contributing reason why undercooled liquid fenofibrate does not instantaneously crystallize and, if compartmentalized into small drops, displays an unprecedented stability against crystallization.

Acknowledgements

This work was supported by the NSF (DMR-1310266) and the Harvard MRSEC (DMR-1420570). Part of this work was performed at the Center for Nanoscale Systems (CNS), a member of the National Nanotechnology Infrastructure Network (NNIN), which is supported by the National Science Foundation under NSF award no. ECS-0335765. CNS is part of Harvard University.

Notes and references

- 1 R. Laitinen, K. Lobmann, C. J. Strachan, H. Grohganz and T. Rades, *International Journal of Pharmaceutics*, 2013, **453**, 65-79.
- 2 C. Brough and R. O. Williams, III, International Journal of 25 Pharmaceutics, 2013, **453**, 157-166.
- 3 Y. Kawabata, K. Wada, M. Nakatani, S. Yamada and S. Onoue, International Journal of Pharmaceutics, 2011, **420**, 1-10.
- 4 J. A. Baird, D. Santiago-Quinonez, C. Rinaldi and L. S. Taylor, *Pharmaceutical Research*, 2012, **29**, 271-284.

- 5 A. Paudel, Z. A. Worku, J. Meeus, S. Guns and G. Van den Mooter, *International Journal of Pharmaceutics*, 2013, 453, 253-284.
- 6 P. A. Priemel, R. Laitinen, S. Barthold, H. Grohganz, V.-P. Lehto, T. Rades and C. J. Strachan, *International Journal of Pharmaceutics*, 2013, **456**, 301-306.
- 7 Y. C. Ng, Z. Yang, W. J. McAuley and S. Qi, *European Journal* of Pharmaceutics and Biopharmaceutics, 2013, **84**, 555-565.
- 8 E. Amstad, M. Gopinadhan, C. Holtze, C. O. Osuji, M. P. Brenner, F. Spaepen and D. A. Weitz, *accepted in Science*.
- 9 Y. N. Xia and G. M. Whitesides, Annual Review of Materials Science, 1998, 28, 153-184.
- 10 A. Rotem, A. R. Abate, A. S. Utada, V. Van Steijn and D. A. Weitz, *Lab on a Chip*, 2012, **12**, 4263-4268.
- 11 D. Law, W. L. Wang, E. A. Schmitt, Y. H. Qiu, S. L. Krill and J. J. Fort, *Journal of Pharmaceutical Sciences*, 2003, **92**, 505-515.
- 12 K. F. Kelton and A. L. Greer, Nucleation in condensed matter applications in materials and biology, Elsevier, 2010.
- 13 R. F. Henry, G. Z. Zhang, Y. Gao and I. S. Buckner, *Acta Crystallographica Section E-Structure Reports Online*, 2003, **59**, 0699-0700.
- 14 W. K. Burton, N. Cabrera and F. C. Frank, *Nature*, 1949, **163**, 398-399.
- S. D. Peteves and R. Abbaschian, Metallurgical Transactions a-Physical Metallurgy and Materials Science, 1991, 22, 1271-1286.
- 16 A. Kolmogorov, *Izv. Akad. Nauk SSSR, Ser. Math*, 1937, 335-360.
 17
- R. Laitinen, K. Lobmann, C. J. Strachan, H. Grohganz and T. Rades, International Journal of Pharmaceutics, 2013, 453, 65-79.
- 19 2. C. Brough and R. O. Williams, III, International Journal of Pharmaceutics, 2013, **453**, 157-166.
- Y. Kawabata, K. Wada, M. Nakatani, S. Yamada and S. Onoue, *International Journal of Pharmaceutics*, 2011, 420, 1-10.
- J. A. Baird, D. Santiago-Quinonez, C. Rinaldi and L.
 S. Taylor, *Pharmaceutical Research*, 2012, **29**, 271-284.
- 22 5. A. Paudel, Z. A. Worku, J. Meeus, S. Guns and G. Van den Mooter, *International Journal of Pharmaceutics*, 2013, **453**, 253-284.
- P. A. Priemel, R. Laitinen, S. Barthold, H. Grohganz, V.-P. Lehto, T. Rades and C. J. Strachan, International Journal of Pharmaceutics, 2013, 456, 301-306.
- 24 7. Y. C. Ng, Z. Yang, W. J. McAuley and S. Qi, European Journal of Pharmaceutics and Biopharmaceutics, 2013, **84**, 555-565.
 - E. Amstad, M. Gopinadhan, C. Holtze, C. O. Osuji,
 M. P. Brenner, F. Spaepen and D. A. Weitz, *accepted in Science*.
 - 9. Y. N. Xia and G. M. Whitesides, *Annual Review of Materials Science*, 1998, **28**, 153-184.

26

- 27 10. A. Rotem, A. R. Abate, A. S. Utada, V. Van Steijn and D. A. Weitz, *Lab on a Chip*, 2012, **12**, 4263-4268.
- 28 11. D. Law, W. L. Wang, E. A. Schmitt, Y. H. Qiu, S. L.
 Krill and J. J. Fort, *Journal of Pharmaceutical Sciences*, 2003, 92, 505-515.
- E. Amstad, M. Gopinadhan, C. Holtze, C. O. Osuji,
 M. P. Brenner, F. Spaepen and D. A. Weitz, *Science*, 2015, 349, 956-960.
- 30 13. K. F. Kelton and A. L. Greer, *Nucleation in condensed matter applications in materials and biology*, Elsevier, 2010.
- 31 14. R. F. Henry, G. Z. Zhang, Y. Gao and I. S. Buckner, Acta Crystallographica Section E-Structure Reports Online, 2003, **59**, 0699-0700.
- 32 15. W. K. Burton, N. Cabrera and F. C. Frank, *Nature*, 1949, **163**, 398-399.

Physical Chemistry Chemical Physics Accepted Manuscript